Clinical trials: in Mexico
Dengue
A Study to Assess the Efficacy, Safety and Pharmacokinetics of EYU688 in Patients With Dengue Fever
The purpose of this study is to characterize the effect on dengue viral load, fever clearance time as well as on clinical signs and symptoms with the treatment of EYU688 compared with placebo in patients with dengue fever.
- Trial name
- NCT06006559
- Testing
- EYU688
- Where
- 27 sites in Brazil, Colombia and 5 more
- Volunteers
- 108 people
- Sponsor
- Novartis Pharmaceuticals
Adhesive Capsulitis, Frozen Shoulder
GDS Method for Frozen Shoulder
This randomized exploratory clinical trial evaluated the effectiveness of the GDS Muscle and Joint Chains Method compared with conventional physiotherapy in patients with frozen shoulder (adhesive capsulitis).
- Trial name
- NCT07816679
- Testing
- GDS Muscle and Joint Chains Method, Conventional Physiotherapy
- Where
- Mexico
- Volunteers
- 30 people
- Sponsor
- Anahuac University
Dermatomyositis
A Study to Investigate the Efficacy and Safety of Brepocitinib in Adults With Dermatomyositis
This is a phase 3, multicenter, randomized, placebo-controlled, double-blind study of treatment with brepocitinib (TYK2/JAK1 inhibitor) in adults with dermatomyositis (DM).
- Trial name
- VALOR (NCT05437263)
- Testing
- Brepocitinib
- Where
- 109 sites in United States, Argentina and 20 more
- Volunteers
- 241 people
- Sponsor
- Priovant Therapeutics, Inc.
Type 2 Diabetes
A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin
The main purpose of this study is to assess efficacy and safety of orforglipron compared with oral semaglutide in participants with Type 2 diabetes and inadequate glycemic control with metformin.The study will last around 61…
- Trial name
- ACHIEVE-3 (NCT06045221)
- Testing
- Orforglipron, Semaglutide
- Where
- 131 sites in United States, Argentina and 4 more
- Volunteers
- 1,698 people
- Sponsor
- Eli Lilly and Company
Myositis
A Study to Understand How the Study Medicine (PF-06823859) Works in People With Active Idiopathic Inflammatory Myopathies [Dermatomyositis (DM) and Polymyositis (PM)]
The purpose of the study is to understand how the study medicine PF-06823859 (dazukibart) works in people with idiopathic inflammatory myopathies (DM and PM).
- Trial name
- NCT05895786
- Testing
- PF-06823859
- Where
- 138 sites in United States, Argentina and 18 more
- Volunteers
- 318 people
- Sponsor
- Pfizer
Developmental and Epileptic Encephalopathy
A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathies (DEE)
This (DEEp OCEAN Study) is a double-blind, randomized, placebo-controlled, multicenter study to investigate the efficacy, safety, and tolerability of LP352 in the treatment of seizures in children and adults with DEE.
- Trial name
- NCT06719141
- Testing
- LP352
- Where
- 116 sites in United States, Australia and 15 more
- Volunteers
- 367 people
- Sponsor
- Longboard Pharmaceuticals
Ataxia-Telangiectasia (A-T), Ataxia-Telangiectasia
Sirolimus Treatment in Pediatric Patients With Ataxia-Telangiectasia
Ataxia-telangiectasia (A-T) is a progressive disease which is, to date, incurable, affecting motor skills, and a high cancer and recurrent infections risk.
- Trial name
- NCT07820579
- Testing
- Rapamune (sirolimus/rapamycin)
- Where
- Mexico
- Volunteers
- 6 people
- Sponsor
- Sara Elva Espinosa Padilla, MD
Juvenile Idiopathic Arthritis
Study of Oral Upadacitinib and Subcutaneous/Intravenous Tocilizumab to Evaluate Change in Disease Activity, Adverse Events and How Drug Moves Through the Body of Pediatric and Adolescent Participants With Active Systemic Juvenile Idiopathic Arthritis.
Juvenile Idiopathic Arthritis (JIA) is the most common type of arthritis that affects children. The term "idiopathic" means "of unknown origin".
- Trial name
- SELECT-sJIA (NCT05609630)
- Testing
- Upadacitinib, Tocilizumab
- Where
- 45 sites in United States, Argentina and 15 more
- Volunteers
- 90 people
- Sponsor
- AbbVie
Chronic Obstructive Pulmonary Disease
Study of Clinical and Patient-reported Outcomes in Adults With Moderate to Severe COPD Treated With Breztri/Trixeo
Chronic Obstructive Pulmonary Disease is a leading cause of global morbidity and mortality, especially in low- and middle-income countries. Exacerbations accelerate disease progression and increase the risk of death.
- Trial name
- iCHOROS (NCT07069829)
- Where
- 36 sites in Argentina, Colombia and 10 more
- Volunteers
- 1,400 people
- Sponsor
- AstraZeneca
Generalized Myasthenia Gravis
Phase 3 Study to Assess the Efficacy and Safety of Batoclimab as Induction and Maintenance Therapy in Adult Participants With Generalized Myasthenia Gravis
The purpose of this 4-period study is to confirm the efficacy and safety of batoclimab in participants with gMG. In Period 1, participants will be randomized 1:1:1 to receive batoclimab 680 milligrams (mg) subcutaneously (SC)…
- Trial name
- NCT05403541
- Testing
- Batoclimab 680 mg SC weekly, Batoclimab 340 mg SC weekly, Batoclimab 340 mg SC bi-weekly
- Where
- 93 sites in United States, Argentina and 14 more
- Volunteers
- 233 people
- Sponsor
- Immunovant Sciences GmbH
Schizophrenia
A Study for Participants With Schizophrenia
The purpose of this study is to test the hypothesis that 1 or more dose levels of LY2140023 given orally to participants with schizophrenia twice daily for 4 weeks will have significantly greater effect than placebo.
- Trial name
- NCT00520923
- Testing
- LY2140023, Olanzapine
- Where
- 35 sites in Argentina, Austria and 7 more
- Volunteers
- 669 people
- Sponsor
- Denovo Biopharma LLC
Anaplastic Large Cell Lymphoma, ALK-Negative, Follicular Helper T-Cell Lymphoma
Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy
This phase III trial compares the effect of high dose chemotherapy and the patients' own (autologous) stem cells to observation only in patients with peripheral T-cell lymphoma who achieved a complete response after initial…
- Conditions
- Anaplastic Large Cell Lymphoma, ALK-Negative, Follicular Helper T-Cell Lymphoma, Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type, Peripheral T-Cell Lymphoma, Not Otherwise Specified
- Trial name
- NCT06724237
- Testing
- Autologous Hematopoietic Stem Cell Transplantation, Best Practice, Biospecimen Collection
- Where
- 165 sites in United States, Mexico
- Volunteers
- 294 people
- Sponsor
- Eastern Cooperative Oncology Group
Moderately to Severely Active Ulcerative Colitis
A Study to Assess the Efficacy and Safety of Afimkibart (Also Known as RO7790121) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis
This Phase III, multicenter, double-blind, placebo-controlled, treat-through study will evaluate the efficacy and safety of Afimkibart (RO7790121) compared with placebo in participants with moderately to severely active…
- Trial name
- Ametrine-1 (NCT06589986)
- Testing
- Afimkibart
- Where
- 184 sites in United States, Argentina and 28 more
- Volunteers
- 400 people
- Sponsor
- Hoffmann-La Roche
Cognitive Impairment
Synbiotic LA-5 and Agave Inulin for Mild Cognitive Impairment
This pilot randomized, double-blind, crossover clinical trial will evaluate the effect of a synbiotic containing Lactobacillus acidophilus LA-5 and agave inulin on mild cognitive impairment (MCI) in adults aged 60-75 years…
- Trial name
- NCT07818369
- Testing
- Synbiotic (Lactobacillus acidophilus LA-5 and Agave Inulin) Intervention Type:
- Where
- Mexico
- Volunteers
- 20 people
- Sponsor
- Anahuac University
OSA, Overweight or Obesity
A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or Overweight
Study GZRA is a master protocol that will support 2 independent studies, GZ01 and GZ02. Participants will be assigned to the appropriate study prior to randomization.
- Trial name
- ATTAIN-OSA (NCT06649045)
- Testing
- Orforglipron
- Where
- 66 sites in United States, Argentina and 7 more
- Volunteers
- 712 people
- Sponsor
- Eli Lilly and Company
Breast Cancer
Comparison of Fulvestrant (FASLODEX™) 250 mg and 500 mg in Postmenopausal Women With Oestrogen Receptor Positive Advanced Breast Cancer Progressing or Relapsing After Previous Endocrine Therapy.
The purpose of this study is to evaluate the efficacy of a new dose of 500 mg Fulvestrant with the standard dose of 250 mg in postmenopausal women with oestrogen receptor positive advanced breast cancer who have failed on a…
- Trial name
- CONFIRM (NCT00099437)
- Testing
- Fulvestrant
- Where
- 106 sites in United States, Belgium and 15 more
- Volunteers
- 736 people
- Sponsor
- AstraZeneca
Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)
This is a Phase III, randomized, open-label multicenter study that will evaluate the efficacy and safety of giredestrant compared with fulvestrant, both in combination with the investigator's choice of a CDK4/6 inhibitor…
- Trial name
- NCT06065748
- Testing
- Giredestrant, Fulvestrant, Abemaciclib
- Where
- 311 sites in United States, Argentina and 35 more
- Volunteers
- 1,050 people
- Sponsor
- Hoffmann-La Roche
Breast Cancer, Solid Tumors
A Study to Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid Tumors
The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called PF-07220060 and PF-07104091) in people with breast cancer. This clinical study consists of 2 parts (part 1 and part 2).
- Trial name
- NCT05262400
- Testing
- PF-07220060 + PF-07104091 combination dose escalation, PF-07104091 + PF-07220060 + fulvestrant dose expansion, PF-07104091 + PF-07220060 + letrozole dose expansion
- Where
- 44 sites in United States, Argentina and 7 more
- Volunteers
- 235 people
- Sponsor
- Pfizer
Ovarian Cancer
Study to Assess Prevalence of the Folate Receptor Alpha (FRa) in Adult Female Participants With Ovarian Cancer in Intercontinental (InterCon) Countries
Epithelial ovarian cancer (OC), including fallopian tube and primary peritoneal cancer, is the deadliest gynecologic malignant neoplasm with a 5-year relative survival of approximately 50%.
- Trial name
- ConFeR (NCT07539844)
- Where
- 12 sites in Argentina, Brazil and 3 more
- Volunteers
- 1,000 people
- Sponsor
- AbbVie
HPV Positive Oropharyngeal Squamous Cell Carcinoma, HIV-1-infection
Nine-valent HPV Vaccine to Prevent Persistent Oral HPV Infection in Men Living With HIV
This is a randomized, double-blinded, placebo-controlled Phase III interventional trial of the nine-valent HPV vaccine (9vHPV) to prevent persistent oral HPV infection in adult men living with HIV.
- Conditions
- HPV Positive Oropharyngeal Squamous Cell Carcinoma, HIV-1-infection, HPV Infection
- Trial name
- NCT04255849
- Testing
- 9 valent human papillomavirus vaccine (Types 6, 11, 16, 18, 31, 33, 45, 52, 58)
- Where
- 3 sites in Brazil, Mexico and 1 more
- Volunteers
- 700 people
- Sponsor
- Weill Medical College of Cornell University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.